Oral Amiodarone Dosing for Atrial Fibrillation with Rapid Ventricular Response
For AF with RVR, start oral amiodarone at 600-800 mg per day in divided doses until a total loading dose of 10 grams is achieved, then reduce to 200 mg daily for maintenance. 1
Loading Phase Dosing
The standard oral loading regimen consists of:
- 600-800 mg daily in divided doses (typically 200-400 mg three times daily)
- Continue until cumulative dose of 10 grams is reached (approximately 10-14 days at 800 mg/day)
- Can be administered in inpatient or outpatient settings 1
Higher initial dosing (up to 1,600 mg/day) may be used in unstable inpatients, though this increases toxicity risk 1. For hemodynamically stable patients, the 600-800 mg/day regimen is preferred as it balances efficacy with safety.
Maintenance Phase
After achieving the 10-gram loading dose:
- 200 mg daily is the standard maintenance dose 1
- Some patients may require 200-400 mg daily depending on response 1
Clinical Context and Considerations
Amiodarone is particularly beneficial in AF with RVR when:
- Patients have impaired renal function (unlike other antiarrhythmics) 1
- Heart failure or reduced ejection fraction is present (low proarrhythmia risk) 2, 3
- Structural heart disease exists (contraindication for class IC agents) 4
However, the 2006 ACC/AHA/ESC guidelines note that intravenous amiodarone is only Class IIa for rate control when other measures fail or are contraindicated 5. For oral use specifically for rate control, the 2014 AHA/ACC/HRS guidelines classify it as Class IIb - meaning it "may be considered" when beta-blockers, calcium channel blockers, or digoxin fail to control rate adequately 3.
Important Caveats
Rate control vs. rhythm control distinction matters: The dosing above is designed for rhythm control (cardioversion). If your goal is purely rate control in AF with RVR, beta-blockers or calcium channel blockers should be first-line, not amiodarone 5, 3. Amiodarone for rate control alone is reserved for refractory cases.
Conversion timeline: Most conversions to sinus rhythm occur 6-8 hours after initiation with oral loading, though full effect may take days 4. One study showed mean conversion time of 20 hours with oral dosing 6.
Toxicity concerns: The most serious adverse effect is pulmonary toxicity (historically 2-17%, lower with doses ≤300 mg/day maintenance) 1. Other significant risks include:
- Bradycardia and QT prolongation 1
- Thyroid, liver, and ocular toxicity (dose and duration dependent) 1
- GI upset and constipation 1
Use the lowest effective dose and monitor closely, as toxicity correlates with cumulative exposure 1.
Alternative Approach: Combined IV/Oral Loading
If more rapid control is needed but IV-only therapy isn't feasible, you can combine routes:
- Start with 300 mg IV over 1 hour followed by oral dosing 7, 8
- Then continue with 600 mg/day orally in divided doses for one week
- Followed by 400 mg/day for three weeks 7, 8
This approach achieved 85% conversion rates in one study 8.
Predictors of Success
Factors favoring successful cardioversion:
Patients with large left atria and long-standing AF may require prolonged therapy or may not convert 7.